A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas

BACKGROUND: Bortezomib targets molecular dysregulation of nuclear factor-κB activation and cell cycle control, which are characteristic features of diffuse large B-cell lymphoma (DLBCL). We evaluated the safety and efficacy of bortezomib treatment with dose-dense cyclophosphamide, doxorubicin, vincr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jeong Eun, Yoon, Dok Hyun, Jang, Geundoo, Lee, Dae Ho, Kim, Shin, Park, Chan-Sik, Huh, Jooryung, Kim, Won Seog, Park, Jinny, Lee, Jae Hoon, Lee, Soon Il, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317471/
https://www.ncbi.nlm.nih.gov/pubmed/22479278
http://dx.doi.org/10.5045/kjh.2012.47.1.53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317471/
https://www.ncbi.nlm.nih.gov/pubmed/22479278
http://dx.doi.org/10.5045/kjh.2012.47.1.53

Ejemplares similares